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The fermented extract of wheat germ, trade name Ave-
mar, is a complex mixture of biologically active mole-
cules with potent anti-metastatic activities in various
human malignancies. Here we report the effect of Ave-
mar on Jurkat leukemia cell viability, proliferation, cell
cycle distribution, apoptosis, and the activity of key gly-
colytic/pentose cycle enzymes that control carbon flow
for nucleic acid synthesis. The cytotoxic IC50 concentra-
tion of Avemar for Jurkat tumor cells is 0.2 mg/ml, and
increasing doses of the crude powder inhibit Jurkat cell
proliferation in a dose-dependent fashion. At concentra-
tions higher than 0.2 mg/ml, Avemar inhibits cell growth
by more than 50% (72 h of incubation), which is preceded
by the appearance of a sub-G1 peak on flow histograms
at 48 h. Laser scanning cytometry of propidium iodide-
and annexin V-stained cells indicated that the growth-
inhibiting effect of Avemar was consistent with a strong
induction of apoptosis. Inhibition by benzyloxycar-
bonyl-Val-Ala-Asp fluoromethyl ketone of apoptosis but
increased proteolysis of poly(ADP-ribose) indicate
caspases mediate the cellular effects of Avemar. Activi-
ties of glucose-6-phosphate dehydrogenase and transke-
tolase were inhibited in a dose-dependent fashion,
which correlated with decreased 13C incorporation and
pentose cycle substrate flow into RNA ribose. This de-
crease in pentose cycle enzyme activities and carbon
flow toward nucleic acid precursor synthesis provide
the mechanistic understanding of the cell growth-con-
trolling and apoptosis-inducing effects of fermented
wheat germ. Avemar exhibits about a 50-fold higher IC50
(10.02 mg/ml) for peripheral blood lymphocytes to in-
duce a biological response, which provides the broad
therapeutic window for this supplemental cancer treat-
ment modality with no toxic effects.
The preventive and therapeutic potential of two natural
wheat products, wheat bran and fermented wheat germ (Ave-
mar), in experimental carcinogenesis has recently been de-
scribed (1, 2). Although no chemical constituents are yet iso-
lated and tested experimentally, it is likely that benzoquinones
and wheat germ agglutinin in wheat germ and fiber and lipids
and phytic acid in wheat bran play a significant role in exerting
anti-carcinogenic effects. In a recent report utilizing intracel-
lular carbon flow studies with a 13C-labeled isotope of glucose
and biological mass spectrometry (GC/MS),1 it was demon-
strated that the crude powder of fermented wheat germ dose-
dependently inhibits nucleic acid ribose synthesis primarily
through the nonoxidative steps of the pentose cycle while in-
creasing direct glucose carbon oxidation and acetyl-CoA utili-
zation toward fatty acid synthesis in pancreatic adenocarci-
noma cells (3). These metabolic changes indicate that
fermented wheat germ exerts its anti-proliferative action
through altering metabolic enzyme activities, which primarily
control glucose carbon flow toward nucleic acid synthesis.
In vivo, Avemar has a marked inhibitory effect on metastasis
formation in tumor-bearing animals (4), and this effect is at-
tributed to its immune-restorative properties (5), which result
in a decreased survival time of skin grafts and reduced cell
proliferation while enhancing apoptosis. Avemar remarkably
inhibits tumor metastasis formation after chemotherapy and
surgery in clinically advanced colorectal cancers. Patients re-
ceiving standard surgical and chemopreventive therapies for
their advanced colorectal cancers developed significantly less
new metastases during the 9-month follow-up period when
treated with additional 9 g/day Avemar daily (6, 7). In a recent
randomized clinical study report Avemar significantly pro-
longed (doubled) time-to-progression in high-risk melanoma
patients (8).
Many anticancer drugs have been shown to induce cell death
through the induction of apoptosis. It is well known that apo-
ptosis is a well controlled process by a programmed set of
cellular events partially mediated by caspases. A large number
of substrates for caspases have been reported, including poly-
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(ADP-ribose) polymerase (PARP), a 116-kDa nuclear DNA re-
pair enzyme that is cleaved during apoptosis by caspases-3 and
-7 (9, 10). Powerful and selective reversible and irreversible
peptide-based inhibitors are also available to better character-
ize and understand the mechanism(s) of how caspases regulate
apoptosis. The tripeptide benzyloxycarbonyl-Val-Ala-Asp flu-
oromethyl ketone (Z-VAD.fmk) is a broadly used general
caspase inhibitor that blocks apoptosis in many cell types,
including human leukemic Jurkat T cells (10, 11).
Here we report the effect of fermented wheat germ on cell
cycle regulation, proliferation, and apoptosis induction in Jur-
kat leukemia cell cultures. Our results confirm strong tumor
growth inhibitory properties of Avemar and additionally reveal
its cell cycle-regulating characteristics. Avemar decreases
G6PDH and transketolase activities that are key enzymes in-
volved in glucose conversion into the five-carbon nucleotide
precursor ribose pool. Stable isotope studies indicate that Ave-
mar is a powerful inhibitor of de novo nucleic acid synthesis.
This likely is the underlying mechanism of the anti-prolifera-
tive tumor growth-controlling and apoptosis-inducing potential
of fermented wheat germ in leukemia tumor cells. On the
contrary, Avemar has no toxic biological effects on PBLs in the
doses that affect tumor cells in an adverse manner.
MATERIALS AND METHODS
Chemicals—Ribose 5-phosphate, xylulose 5-phosphate, MgCl2, tri-
ose-phosphate isomerase, NADH, thiamine pyrophosphate (TPP), glu-
cose 6-phosphate, dithiothreitol, NADP, propidium iodide (PI), Igepal
CA-630, Ponceau S, and vincristine were purchased from Sigma Co. and
Tris from ICN Pharmaceuticals Inc (Costa Mesa, CA). The Bio-Rad
protein assay was purchased from Bio-Rad and the BCA protein assay
from Pierce. Fetal bovine serum, RPMI 1600 medium was purchased
from Invitrogen (Carlsbad, CA). Dulbeccos phosphate-buffered saline
(PBS), typsin-EDTA and solution C (0.05% trypsin and EDTA (1:500) in
PBS) were purchased from Biological Industries (Kibbutz Beit Haemek,
Israel). Nitrocellulose strips were purchased from Schleicher & Schuell
(Postach, Dasell, Germany). Annexin V was purchased from Bender
MedSystems (Vienna, Austria), PARP from BD PharMingen cat. 66391
A and clone 7D3-6) and the secondary antibody anti-mouse immuno-
globulin from DAKO (Copenhagen, Denmark). ECL was purchased
from Amersham Biosciences. FK-109 Z-VAD.fmk were from Enzyme
Sysytems Products (Livermore, CA). Avemar was kindly provided by
Biromedicina, Co. (Budapest, Hungary) through a material and chem-
ical transfer agreement.
Cell Culture—Jurkat cells (acute lymphoid T-cell leukemia) were
purchased from ATCC and cultured in RPMI 1640 medium supple-
mented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-gluta-
mine, and antibiotics: 100 units/ml penicillin and 100 g/ml streptomy-
cin (Invitrogen). Cells were grown in an isolated 37 °C, 5% CO2 tissue
incubator compartment. Cells were plated in 0.2–1  105 cells/ml den-
sity for the enzyme kinetics experiments in T75 culture flasks. For
apoptosis, necrosis, and cell cycle studies cells were seeded into 6-well
plates at 5  105 cells/well density. Avemar was added to the cultures
after 1 h of equilibration in the cell culture chambers after seeding.
Avemar was dissolved in Dulbecco’s PBS for all experiments. Control
cultures were treated with an equal volume of PBS as the Avemar-
treated cultures. Jurkat cell cultures used in this study were free of
mycoplasm infection as shown by the Gen-probe rapid mycoplasm de-
tection system prior to treatments with Avemar. Peripheral blood
mononuclear cells from healthy donors were isolated from buffy coat
cells using the Ficoll gradient method (12); further purification of lym-
phocytes from peripheral blood mononuclear cells was performed by
depletion of contaminating cells by adherence to plastic plates for 4 h.
PBL were used as non-dividing and non-tumor cells to test the apopto-
sis-inducing effects of Avemar in a control cell system.
Cell Cycle Analysis—Jurkat cells were harvested after Avemar treat-
ment and stained in Tris-(hydroxymethyl)aminomethane-buffered sa-
line containing PI (50 g/ml), ribonuclease A (10 g/ml), and Igepal
CA-630 (0.1%) for 1 h at 4 °C. DNA content was analyzed by fluores-
cence-activated cell sorting (FACS). Fluorescence of 12,000 Jurkat cells
was acquired for each histogram and then analyzed using the Multi-
cycle program interface (Phoenix Flow Systems, San Diego, CA). Flow
cytometry DNA histograms were collected in triplicates on an XL flow
cytometer (Coulter Corporation, Hialeah, FL).
Cell Viability Assay—Cell number was determined by the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (13).
20,000 Jurkat cells per well were incubated in 96-well plates in the
presence or in the absence of Avemar at different concentrations. Vin-
cristine was used as a positive control for apoptosis induction. The blue
MTT formazan precipitate was dissolved in 100 l of Me2SO, and the
absorbance values at 550 nm were determined on a multiwell plate
reader. For peripheral blood cells, 500,000 cells were seeded in 12-well
plates in the presence or in the absence of Avemar at different concen-
trations. Viability was estimated by a MultiziserIIL Coulter (Beckman
Coulter, Fullerton, CA) to count the cells and by FACS analysis adding
18 g/ml PI (Sigma Co.) staining method without cell permeabilization.
The fluorescence of cells was analyzed by flow cytometry using an Epics
XL flow cytometers (Beckman Coulter, Fullerton, CA). Only non-viable
cells are PI positives as indicated by previous studies (14).
Assessment of Apoptosis by Flow Cytometry and LSC—Jurkat cells
after Avemar treatment were washed once in binding buffer (10 mM
HEPES, sodium hydroxide, pH 7.4, 140 mM sodium chloride, 2.5 mM
calcium chloride) and resuspended in the same buffer at 106 cells ml1
in the presence of 0.5 l of annexin V-FITC. After 30 min of incubation
at room temperature, PI was added at 0.05 g ml1 (11). The fluores-
cence of cells was analyzed by FC and LSC. Approximately 3  104 cells
were tested for each histogram for FC and 1500 cells for LSC.
Gel Electrophoresis and Immunoblotting of PARP—To analyze
PARP, SDS-page electrophoresis (15) and immunoblotting were per-
formed as previously described (16). Briefly, 30 g of the protein extract
was used on an 8% polyacrylamide gel and transferred to Protean
membranes (Schleicher & Schuell, GmbH, Postach, Dasell, Germany).
Monoclonal antibodies either against PARP were used at a 1:1000
dilution. As a control of protein loading the blot membrane was stained
with Red Ponceau. The reaction was visualized with a secondary anti-
body (anti-mouse immunoglobulin, DAKO) conjugated to horseradish
peroxidase diluted 1:1000 in bovine serum albumin/Tween-20/PBS and
the enhanced chemiluminescence (ECL) detection kit (Amersham Bio-
sciences). PARP immunoblotting was performed after 48 h of incubation
with the Avemar and vincristine. The protein concentration of cell
extracts was determined by the BCA protein assay.
Measurements of Enzyme Activities—Jurkat cells treated with in-
creasing doses of Avemar were lysed in 1 ml of 20 mM Tris buffer (pH
7.5) containing 1 mM dithioerythreitol and 0.2 mM phenylmethylsulfo-
nyl fluoride, 1 mM K-EDTA, 0.2 g/liter Triton X-100, and 0.2 g/liter
sodium deoxycholate. Cell extracts were stored at 20 °C for 24 h. The
homogenates were then defrosted in an ice bath, sonicated in a Brason–
2000 cell disintegrator for 5 min, ultracentrifuged at 100,000  g for
1 h, and the supernatant used for enzyme activity assays as described
below.
Transketolase (EC 2.2.1.1) activity was determined using the en-
zyme-linked method of De La Haba et al. (17). 1-ml aliquots of transke-
tolase free buffer were measured in spectrophotometry cuvettes con-
taining 50 mM Tris-HCl, pH 7.6, 2 mM ribose 5-phosphate, 1 mM
xylulose 5-phosphate, 5 mM MgCl2, 0.2 units/ml triose-phosphate
isomerase/-glyceraldehyde-3-phosphate dehydrogenase, 0.2 mM
NADH, and 0.1 mM thiamine pyrophosphate. The transketolase reac-
FIG. 1. Jurkat leukemia cell proliferation in response to Ave-
mar treatment. Jurkat cell cultures were treated with increasing
doses of Avemar as indicated on the x axis; their viability and prolifer-
ation were determined by formazan dye uptake and expressed as per-
cent of untreated control cell proliferation (A). 1 mg/ml Avemar inhib-
ited cell proliferation in a time course study of up to 72 h in culture (B).
Mean  S.D., n  9; *, p  0.05; **, p  0.01.
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tion was initiated by the addition of 25 and 50 l of cell extract at 37 °C.
The oxidation of NADH, which is directly proportional to transketolase
activity, was measured by the decrease in 340-nm absorbance. Tran-
sketolase activity is expressed as nmol/min/million cells.
Glucose-6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49) activity
was measured as described by Tian et al. (18). Briefly, cuvettes were
prepared with a 50 mM Tris-HCl, pH 7.6 buffer, containing 2 mM glucose
6-phosphate and 0.5 mM NADP. Reactions were initiated by the addi-
tion of 25 and 50 l of cell extract at 37 °C. The reduction of NADP,
which is directly proportional to G6PDH activity, was quantified by the
increase in 340-nm absorbance, and G6PDH activity is expressed as
nmol/min/million cells.
Lactate dehydrogenase (LDH; EC 1.1.1.27) activity was measured as
described by Mommsen et al. (19). The assay medium for lactate dehy-
drogenase contained 50 mM Tris-HCl buffer, pH 7.6, 0.2 mM NADH, and
5 mM pyruvate (omitted for control). The oxidation of NADH, which is
directly proportional to lactate dehydrogenase activity, was measured
by the decrease in 340-nm absorbance. LDH activity is expressed as
nmol/min/million cells.
Hexokinase (HK; EC 2.7.1.1) activity was measured by the enzyme-
linked method of Grossbard and Schimke (20). Briefly, cuvettes were
prepared with a 50 mM Tris-HCl, pH 7.6 buffer, containing 10 mM
glucose, 1 mM NADP, 2 mM ATP, 10 mM magnesium chloride, and 1
unit of G6PDH. Reactions were initiated by the addition of 50 and 100
l of cell extract at 37 °C. The reduction of NADP, which is directly
proportional to HK activity, was quantified by the increase in 340-nm
absorbance, and HK activity is expressed as nmol/min/million cells.
Stable Isotope Incorporation into RNA Ribose—In order to measure
actual substrate carbon flow in the pentose cycle and glycolysis, which
are controlled by the enzymes listed above, we utilized stable isotope-
based metabolic profiling as introduced for drug effect studies in cancer
(21). Jurkat cell continuous S phase-independent nucleic acid synthesis
rates were measured by the incorporation of [1,2-13C2]glucose into RNA
ribose as the single tracer and biological mass spectrometry. 13C label
accumulation into RNA was determined by measuring the molar en-
richment (ME) of ribose using chemical ionization methods, which is
capable of determining both total activity (mn) and positional dis-
tribution of 13C labels in nucleic acid ribose as described previously (22,
23).
Stable Isotope Incorporation into Lactate—Lactate from the cell cul-
ture media (0.2 ml) was extracted by ethyl acetate and derivatized to its
propylamine-HFB form. The m/z 328 (carbons 1–3 of lactate, chemical
ionization) ion cluster was monitored for the detection of m1 (recycled
lactate through the pentose cycle) and m2 (lactate produced by glycol-
ysis) for the estimation of the pentose cycle activity relative to glycolysis
(23).
Gas Chromatography/Mass Spectrometry—Mass spectral data were
obtained on the HP5973 mass selective detector connected to an
HP6890 gas chromatograph. The settings were as follows: GC inlet,
230 °C; transfer line, 280 °C; MS source, 230 °C; MS Quad, 150 °C. An
HP-5 capillary column (30-m length, 250-m diameter, 0.25-m film
thickness, Supelco) was used for ribose analysis at the ion cluster m/z
256 and for lactate analysis (23).
Data Analysis and Statistical Methods—Experiments in vitro were
carried out using three cultures each time for each treatment regimen
and then repeated twice. Mass spectral analyses were carried out by
three independent automatic injections of 1-l samples by the auto-
matic sampler and accepted only if the standard sample deviation was
less than 1% of the normalized peak intensity. Enzyme activity meas-
urements were determined after correction for total protein content in
cell extracts. Statistical analysis was performed using the parametric
unpaired, two-tailed independent sample Student’s t test with 99%
confidence intervals (  2.58) and p  0.01 was considered to indicate
significant differences in glucose carbon metabolism and enzyme activ-
ities with increasing doses of Avemar. Because of the human cell line
involved, a clearance was obtained from the Institutional Review
Boards (IRB) of both Harbor-UCLA and The University of Barcelona for
the use of these commercially available cells for the experiments
reported.
RESULTS
For the present report, Jurkat lymphoid T- cell leukemia
cells were treated with increasing amounts of Avemar for
either 48 or 72 h in order to estimate the growth regulating
effects of this natural anti-cancer nutritional supplement
through cell cycle modulation, apoptosis induction, metabolic
enzyme activity changes as well as substrate flow measure-
ments. Avemar doses of 10 mg/ml (stock) and its serial dilu-
tions were selected for the study because the effective oral
dose of Avemar that inhibits tumor metastasis formation is
9.0 g/day, which is equivalent to an estimated plasma con-
centration of 0.5 and 1 mg/ml in an average (70 kg) weight
patient (6).
Cytotoxic Effects of Avemar on Jurkat cells—Avemar induced
a dose-dependent decrease in vital formazan dye accumulating
cells after 72 h of treatment, ranging from 0 to 10 mg/ml (Fig.
1A). The mean IC50 of Avemar was 0.23  0.03 mg/ml. The
cytotoxicity of Avemar on Jurkat cells was studied using a time
course experiment. A significant increase in cell death by form-
azan exclusion was detected as early as 24 h with 1 mg/ml
Avemar treatment (Fig. 1B). The mean IC50 of vincristine as a
positive control was 0.18  0.02 nM. Avemar exhibited about
50-fold higher IC50 (10.02 mg/ml) for PBLs to induce biological
responses.
Cell Cycle—In control cultures the cell cycle pattern re-
mained constant over time; the percentage of cells in the G0/G1
phase: 40, 39, and 42%; S phase: 35, 39, and 34%; and G2/M
phase: 25, 23, and 23% after 24, 48, and 72 h, respectively (Fig.
2). A complete alteration of the cell cycle patterns became
evident as shown in Fig. 2 by the gray arrows after 48 and 72 h
with 0.5 mg/ml or higher Avemar concentrations. At concen-
trations of 0.7 and 1 mg/ml Avemar, even after 24 h, a broad
peak appeared in the sub-G1 region with a significant decrease
in the S cycle phase. The sub-G1 region is indicative of apo-
ptosis (Fig. 2, black arrows). Although lower concentrations of
Avemar (0.1 and 0.3 mg/ml) induced only minor changes in the
cell cycle distribution of Jurkat cells, they were still effective in
controlling cell growth as there was a significant decrease in
formazan-accumulating Jurkat cells as shown in Fig. 1A.
Induction of Apoptosis—Avemar triggered prominent apo-
ptosis at 0.5 mg/ml dose after 72 h of culturing as demonstrated
by FACS analysis. Increasing doses of Avemar induced more
prominent apoptosis, which also appeared earlier (Fig. 3A). In
order to discriminate between late apoptotic and necrotic cells,
we investigated PI and annexin V-FITC positive cells using
LSC analyses. We observed that all cells with PI/FITC char-
FIG. 2. Jurkat leukemia cell cycle changes in response to Ave-
mar treatment. Jurkat cell cultures were treated with increasing
doses of Avemar as indicated on the right column, and cell cycle distri-
bution was determined using flow cytometry after PI staining expressed
as percent of G0/G1, S, and G2-M cycle phases. The DNA histograms
show that Avemar induced a time- and dose-dependent decrease in the
S cycle phase whereas there was a significant expansion of the G0/G1
cycle phase consistent with an increase in the number of apoptotic
Jurkat cell figures. The typical FACS analysis showed the distinct
signals and cell frequencies associated with the arrested cell cycle
status as described under “Results” (n  6).
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acteristics presented pycnotic nuclei, which is a definite sign of
apoptotic cell formation after treatment with 1 mg/ml Avemar
(72 h). The portion of normal cell figures with LSC was only
5.5%, whereas early apoptotic cells showed 64.5% and late
apoptotic cells 29.3% frequency (Fig. 4). All Avemar-treated
Jurkat cells inside the PI/FITC region presented the typical
green appearance of early apoptosis caused by the labeling of
annexin V by FITC.
Involvement of Caspases in the Apoptotic Effect of AVE-
MAR—Decreased apoptosis-related phosphatidylserine exter-
nalization by specific caspase inhibitors is a routinely used
method to reveal the presence of caspase cascades in the cell
death process. In order to assess the involvement of caspases in
the apoptotic effect of Avemar, we studied whether the caspase
inhibitor Z-VAD.fmk could prevent Avemar-induced phosphati-
dylserine externalization. Jurkat cells incubated for 72 h with
1 mg/ml of Avemar in the presence or absence of 100 M
Z-VAD.fmk showed severely decreased phosphatidylserine ex-
ternalization in both early (annexin V-FTIC/PI) and late
(annexin V-FTIC/PI) apoptotic cells (Fig. 3B).
We also investigated whether incubation of Jurkat cells with
different doses of Avemar induced proteolytic cleavage of
PARP, which is considered to be a hallmark of activation of
caspase-3 like proteases during apoptosis (24, 25). Incubation
of Jurkat cells for 48 h with 0, 0.3, 0.5, and 0.7 mg/ml of Avemar
induced prominent cleavage of PARP at a concentration of 0.5
mg/ml or higher (Fig. 3C).
Transketolase and G6PDH Enzyme Activities—G6PDH and
transketolase are two key enzymes that regulate carbon flow in
the pentose cycle because of their high substrate flux coeffi-
cients and thus regulate ribose synthesis and NADPH produc-
tion for proliferating cells (24–26). Avemar inhibited G6PDH
activity at concentrations of 0.7 mg/ml and higher after 48 h of
treatment, and G6PDH was completely inhibited after 72 h
(Fig. 5A). Transketolase was significantly inhibited with 0.7
and 1 mg/ml Avemar after 72 h of treatment (Fig. 5B).
HK and LDH Enzyme Activities—HK and LDH are two of the
key enzyme in the regulation of glycolytic flux. Avemar inhib-
ited LDH and HK at concentrations of 0.3 mg/ml or higher after
48 h of treatment as shown on Fig. 6.
13C Label Accumulation in Lactate—We observed a decrease
in m2 and m1 13C label in lactate in Avemar-treated Jurkat
cells, which is indicative of decreased glucose uptake and gly-
colysis. Overall carbon flux in the pentose cycle relative to
glycolysis showed a dose-dependent non-significant increase in
Jurkat cells after 2 days of Avemar treatment after 0.1 and 0.5
mg/ml treatments. At the dose of 1 mg/ml Avemar treatment
the pentose cycle showed a rapid 22% decrease relative to
glycolysis, as indicated by decreased m1/m2 13C ratios in lac-
tate (Table I).
13C Label Accumulation in RNA Ribose—In order to esti-
mate nucleic acid precursor synthesis measurements of the
molar enrichment of RNA ribose with 13C from glucose was
FIG. 4. Jurkat leukemia cell apoptosis and necrosis in re-
sponse to Avemar treatment using LSC. Jurkat cell cultures were
treated with 1 mg/ml Avemar (72 h), and the formation of apoptotic and
necrotic Jurkat cell figures was determined using PI and Annexin
V-FITC staining. The majority (64.5%, right bottom quadrant) of Jurkat
cells exhibited early apoptosis as indicated by the limited nuclear frag-
mentation. Late apoptosis/necrosis was present in about 30% (right
upper quadrant) of Jurkat cells with advanced nuclear fragmentation
and limited staining, while the frequency of normal cells dropped to
5.5% as seen in the left bottom quadrant of the LSC screen (n  6).
FIG. 3. Jurkat leukemia cell apoptosis in response to Avemar treatment. A, Jurkat cell cultures were treated with increasing doses of
Avemar as indicated on the x axis, and the number of apoptotic Jurkat cell was determined using flow cytometry after PI and annexin V staining.
24-hour treatment is shown with open bars, 48-h treatment with light gray bars, and 72-h treatment with dark gray bars. It can be depicted that
Avemar induced a time- and dose-dependent increase in apoptosis in Jurkat cells in culture. Time dependence is clear at the 0.5 and 1 mg/ml dose
treatments. Mean  S.D., n  9; *, p  0.05; **, p  0.01. B, percentage of annexin V positive cells after 72 h of treatment with and without the
caspase inhibitor Z-VAD.fmk (100 M) of Avemar-treated cultures (1 mg/ml). Mean  S.D., n  5; **, p  0.01. Positive controls were treated with
1 M of staurosporin (SSP). C, Western blots of extracts prepared from cells treated for 48 h with the indicated concentrations of Avemar (0 control;
0.3, 0.5, or 0.7 mg/ml) and probed with anti-PARP antibody. The position of native PARP (116 kDa) and the proteolytic fragment (85 kDa) is
indicated here.
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carried out because ribosomal and messenger RNAs are con-
tinuously synthesized in tumor cells regardless of their prolif-
erative response, cell cycle alterations and apoptosis formation
in response to anti-carcinogenic treatments. 13C incorporation
from glucose into RNA ribose was significantly and dose-de-
pendently decreased after increasing doses of Avemar treat-
ment (Table II). Increasing doses of Avemar (0.1, 0.5, 1 mg/ml)
decreased glucose carbon incorporation into nucleic acid syn-
thesis by 6, 20.4, and 40.2%, respectively, after 48 h of incuba-
tion, which correlated well with the decrease in G6PDH and
transketolase activities (Figs. 5 and 6).
DISCUSSION
Because of their beneficial nutritional values, wheat germ
and wheat bran are frequently used in human food supple-
ments, breakfast cereals, nutri-bars, and various fiber drink
mixtures; therefore, they are part of the regular Western diet.
Avemar is the first fermented and concentrated wheat germ
extract produced by an optimized process to yield 0.4 mg/g (on
dry matter basis) 2,6-dimethoxy-p-benzoquinone and given as a
nutritional supplement for cancer patients. The suspicion that
wheat germ contains powerful cancer-fighting chemicals is not
new; in his later life, the Nobel laureate biochemist Albert
Szent-Györgyi studied various extracts of the wheat plant ex-
tensively for their anti-carcinogenic effects.
This study investigates the complex responses to Avemar
treatment, a potent natural fermented wheat germ extract
with anticarcinogenic properties, of Jurkat T-progeny leuke-
mia cells in culture. Using flow and laser scanning cytometry
techniques, direct enzyme activity measurements, carbon sub-
strate flow measurements with a 13C-labeled glucose tracer has
enabled us to study a broad range of cellular response mecha-
nisms, such as cell cycle progression, apoptosis, cell prolifera-
tion, and their dose-response to this cancer growth-modifying
agent. Activity changes of four important metabolic enzymes
involved in direct glucose oxidation (G6PDH), non-oxidative
glucose utilization (transketolase) toward nucleic acid synthe-
sis, glycolysis (LDH), and glucose activation (HK) are herein
also reported. Our studies revealed profound differences and a
dose-dependent response of Jurkat leukemia cells that directly
affected metabolic enzyme activities, metabolic pathway sub-
strate flow, apoptosis formation, and cell proliferation in re-
sponse to Avemar. It has previously observed that G6PDH
inhibition leads to an increase in apoptosis formation in tumor
cells of various origins (26, 27). In contrast, Avemar treatment
according to our results is about 50 less effective in peripheral
blood lymphocytes in inducing biological effects, which provides
a comfortable therapeutic window for Avemar to apply in pa-
tients as a supplemental treatment modality with minimal or
no toxic side effects.
It has been proved that the flip-flop of phosphatidylserine
from the inner to the outer plasma membrane leaflet of the cell
is a fundamental characteristic that differentiates apoptosis
from necrosis (28). This early phenomenon during the apoptotic
process is followed by caspase activation, which can specifically
be inhibited and the fact that this inhibitor effectively inhibited
Avemar-induced phosphatidylserine externalization demon-
strated the involvement of caspases in mediating the biological
apoptosis-inducing effects of Avemar. Furthermore, we de-
tected a cleavage of PARP during Avemar-induced apoptosis in
Jurkat cells, which more specifically points to the involvement
of caspase-3 in the cascade that mediates wheat germ-induced
apoptosis. Based on these molecular findings our data also
indicate that the mechanism of how Avemar mitigates metas-
tasis also involves decreasing cell motility.
It has recently been demonstrated that Avemar induces pro-
found metabolic changes in cultured MIA pancreatic adenocar-
cinoma cells using the [1,2-13C2]glucose isotope as the single
tracer and biological gas chromatography/mass spectrometry.
It was concluded that Avemar controls tumor propagation pri-
marily through the regulation of glucose carbon redistribution
between cell proliferation- and cell differentiation-related mac-
romolecules in MIA cells (3). In the present study we again
applied stable isotope-based dynamic metabolic profiling as a
model for measuring metabolic pathway control characteristics
(29) by demonstrating a dose-dependent decrease in substrate
carbon flow toward nucleic acid precursor ribose synthesis and
metabolic enzyme activities (G6PDH, transketolase, HK, and
LDH) in Jurkat leukemia cells treated with comparable doses
of Avemar. Indeed, Jurkat cells also responded with decreased
carbon flow through the pentose cycle toward nucleic acid syn-
thesis and in this study the significant, dose-dependent de-
crease of G6PDH and transketolase are also demonstrated. It is
likely that decreased oxidative ribose synthesis in response to
Avemar treatment in Jurkat cells is not able to supply the
FIG. 5. Jurkat leukemia cell G6PDH (A) and transketolase (B)
enzyme activities in response to 48 and 72 h of Avemar treat-
ment. Avemar inhibited both G6PD and transketolase in a dose- and
time-dependent manner. Mean  S.E.; n  9; *, p  0.05; **, p  0.01.
FIG. 6. Jurkat leukemia cell hexokinase (A) and lactate dehy-
drogenase (B) enzyme activities in response to 48 h of Avemar
treatment. Avemar inhibited both enzymes in Jurkat cells in a dose-
dependent manner. Mean  S.E., n  14; *, p  0.05; **, p  0.01.
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tumor cells’ metabolic needs for reducing equivalents, which
would intensively be used for the reduction of ribonucleotides
to deoxyribonucleotides during DNA replication because Ave-
mar inhibits key enzymes that are critically important both in
nucleic acid ribose synthesis and fatty acid production. The
reversion of transformed cell-specific metabolic changes that
consist of increased glucose utilization for nucleic acid synthe-
sis and proliferation (21, 29) has been shown to be an effective
approach for developing new cancer therapies where natural
products such as Avemar may play a key role as nutritional
supplements with no know toxic effects.
The specific cancer fighting constituents of Avemar are not
yet known. It is likely that multiple naturally produced com-
pounds contained in the crude powder of fermented wheat
germ induce the complex metabolic- and apoptosis-inducing
effects inhibiting multiple tyrosine phosphorylase signaling
cascades and the down-regulation of major histocompatibility
complex I (MHC I) involved in immune protection, migration,
tumor metastasis formation, and growth, as shown in other
in vitro models of leukemia (30). Comparison of the anti-
cancer metabolic effects of Avemar to that of the new effective
anti-leukemia drug Gleevec reveals similarities in the meta-
bolic enzyme and carbon substrate flow modifying effects
toward nucleic acid synthesis. Gleevec inhibits glucose phos-
phorylation and oxidation in the oxidative branch of the
pentose cycle, which is specific to inhibiting the tyrosine
kinase activity of BCR-ABL in myeloid tumor cells (31, 32).
Avemar has additional multiple effects on metabolic en-
zymes, and it simultaneously inhibits oxidative and nonoxi-
dative ribose synthesis as well as the activation of glucose
and glycolysis. Individual components of fermented wheat
germ may be important anticancer natural drugs both as
nutritional supplements and as therapeutic agents after they
have been isolated and identified.
In conclusion, Avemar is a natural fermented wheat germ
extract with no known toxicities, and it is a strong regulator of
leukemia tumor cell macromolecule synthesis, cell cycle pro-
gression, apoptosis, and proliferation. Avemar regulates meta-
bolic enzymes that are involved in glucose carbon redistribu-
tion between proliferation-related structural and functional
macromolecules (RNA, DNA). Avemar treatment results in
profound intracellular metabolic changes that bring devastat-
ing consequences for the proliferation of leukemia cells of the
lymphoid lineage. Although the clinical applicability of Avemar
together with current chemotherapies, surgical interventions,
and radiation therapies has to be determined in controlled
blinded clinical studies, this fermented wheat germ extract has
a clear and definite anti-proliferative action that targets nu-
cleic acid synthesis enzymes and induces cell cycle arrest and
apoptosis through a caspase-based mechanism as reported
herein.
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